This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Gerresheimer Begins Financial Year 2013 With Strong Revenue Growth

DÜSSELDORF, Germany, April 10, 2013 /PRNewswire/ --

  • First-quarter revenues up 10.4% to EUR 296.7m
  • Adjusted EBITDA margin reaches 15.5%
  • Net income grows by 41.7% to EUR  10.2m
  • Adjusted earnings per share increased to EUR 0.36
  • Acquisition in India boosts activities in emerging markets

Gerresheimer AG, one of the leading global partners to the pharma and healthcare industry, increased revenues by 10.4% in the first quarter of the new, 2013 financial year.  "The strong revenue growth in the first quarter largely relates to increased revenues in the Plastic Systems Division. The increase is mostly attributable to higher revenues from engineering services and tools paving the way for future business with drug delivery devices. Our latest acquisitions in India also contributed to the surge in revenues. There is furthermore healthy demand for pharma products overall," said Uwe Röhrhoff, CEO of Gerresheimer AG.

Gerresheimer increased revenues in the first quarter of financial year 2013 ( December 1, 2012 to November 30, 2013) by a substantial 10.4% to EUR 294.7m. The revenue increase was due primarily to strong organic growth in the Plastic Systems Division. This notably generated large revenues with tools and engineering services. There was also favorable demand for drug delivery devices such as insulin pens, asthma inhalers and prefillable glass syringes. Sound revenues were also attributable to primary pharma packaging such as glass injection vials, cartridges as well as plastic containers for solid and liquid medications. The two Indian companies acquired in 2012 - Triveni, a producer of plastic primary pharmaceutical packaging, and Neutral Glass, which produces glass pharmaceutical vials - also contributed to the marked revenue increase compared with the prior year.

The Gerresheimer Group generated adjusted EBITDA of EUR 46.0m in the first quarter of 2013, an increase of 2.1% on the prior-year quarter. The adjusted EBITDA margin was 15.5%, below the 16.8% margin in the comparative period. The main reason for the lower margin was the exceptionally strong revenue growth in engineering services and tools business in the Plastic Systems Division. While the tools business and engineering services have narrower margins, they are important in paving the way for the subsequent production of drug delivery devices. Net income after tax increased relative to the prior-year quarter by 41.7% to EUR 10.2m. Adjusted earnings per share rose by EUR 0.03 to EUR 0.36.

Gerresheimer's capital expenditure in the first quarter of 2013 was EUR 16.6m, EUR 1.7m more than a year earlier. In December 2012, Gerresheimer also purchased 75% of shares in Triveni, the leading Indian producer of pharmaceutical plastic packaging and closures.

Outlook

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs